Latest Breaking News On - Orphan drug designation - Page 8 : comparemela.com

Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024

/PRNewswire/ Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities.

United statesLos angelesProduct development centerPrnewswire transcenta holding limitedTranscenta immune tolerance breaking technologyClinical development centers in princetonGroup headquartersTranslational research centerHolding limitedClinical oncology volumeImmune tolerance breaking technologyOrphan drug designationManufacturing facilityClinical development centersExternal partnering centerSuzhou industrial

PYC Therapeutics Gains FDA Orphan Drug Status

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics, a clinical-stage biotech company, has received Orphan Drug Designation .

Therapeutics limitedOrphan drug designation

ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and.

Hong kongUnited statesYuxiang maHaibo qiuMasa lasicaPrnewswire ascentage pharmaHuafeng wangAscentage pharmaYifan zhaiMd anderson cancer centerAmerican society of clinical oncologySun yat sen university cancer centerZhejiang university school of medicineMajor nationalDana farber cancer instituteChina national medical products administration

Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

South koreaUnited kingdomDan patersonEuropean network of gynaecological oncological trialChugai pharmaceutical co ltdCompany annual report on formExchange commissionRaf and mek programGenfleet therapeutics shanghai incSecura bio incDrug administrationFoundation incVerastem oncologyNew drug applicationBreakthrough therapy designationOrphan drug designation

Pacylex Pharmaceuticals Reports Zelenirstat Phase 1 safety and efficacy data at ASCO 2024

Pacylex Pharmaceuticals Reports Zelenirstat Phase 1 safety and efficacy data at ASCO 2024
torontotelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from torontotelegraph.com Daily Mail and Mail on Sunday newspapers.

United statesMccormick placeCure cancer foundationPacylex pharmaceuticalsReportable incPacylex pharmaceuticals incUs department of defenseAmerican society of clinical oncologyCanada mayAmerican societyClinical oncologyAnnual meetingHodgkin lymphomaOrphan drug designationFast track designation